Representatives from the FDA, medical societies, registries and industry met April 22 in Silver Spring, Md., to discuss creation of an international registry for transcatheter aortic valve replacement (TAVR). The collaboration is the first step in an effort to develop a consortium of cardiovascular registries for broad-based analysis and surveillance of medical devices and clinical outcomes.

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France.

Thomas Wang, M.D., has joined Vanderbilt as director of the Division of Cardiovascular Medicine and the physician-in-chief of the Vanderbilt Heart and Vascular Institute.

Nearly one in seven STEMI patients presenting at centers with PCI capabilities experienced nonsystem delays in door-to-balloon-time, and mortality rates were significantly higher in that patient group compared with nondelayed patients.

The Society for Cardiovascular Angiography and Interventions (SCAI) annual scientific sessions, scheduled for May 8 through 11 in Orlando, will offer late-breaking clinical trials, a congenital heart disease symposium, coronary, peripheral and structural tracks and more.

NPR’s “All Things Considered” interviewed C. Michael Gibson, MD, about his experiences treating victims of the explosions at the Boston Marathon. Gibson, a cardiologist at Beth Israel Deaconess Medical Center in Boston, credited the medical teams in the field and the proximity of the emergency tent for stabilizing the wounded. “[They] may have saved innumerable lives,” he said.

Cath/EP and interventional lab professionals wondering if their pay is competitive are being offered an objective measuring stick from a new research poll, Phoenix-based Springboard Healthcare announced.

OrbusNeich today announced that data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) study published online in JACC: Cardiovascular Interventions demonstrated that the COMBO Dual Therapy Stent met the study’s primary endpoint and was found to be effective in controlling neointimal proliferation.